These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19920100)

  • 1. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
    Mittendorf EA; Wu Y; Scaltriti M; Meric-Bernstam F; Hunt KK; Dawood S; Esteva FJ; Buzdar AU; Chen H; Eksambi S; Hortobagyi GN; Baselga J; Gonzalez-Angulo AM
    Clin Cancer Res; 2009 Dec; 15(23):7381-8. PubMed ID: 19920100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
    Kim MM; Allen P; Gonzalez-Angulo AM; Woodward WA; Meric-Bernstam F; Buzdar AU; Hunt KK; Kuerer HM; Litton JK; Hortobagyi GN; Buchholz TA; Mittendorf EA
    Ann Oncol; 2013 Aug; 24(8):1999-2004. PubMed ID: 23562929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.
    Ladoire S; Arnould L; Mignot G; Apetoh L; Rébé C; Martin F; Fumoleau P; Coudert B; Ghiringhelli F
    Br J Cancer; 2011 Jul; 105(3):366-71. PubMed ID: 21750556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
    Bayraktar S; Gonzalez-Angulo AM; Lei X; Buzdar AU; Valero V; Melhem-Bertrandt A; Kuerer HM; Hortobagyi GN; Sahin AA; Meric-Bernstam F
    Cancer; 2012 May; 118(9):2385-93. PubMed ID: 21953213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.
    Natoli C; Vici P; Sperduti I; Grassadonia A; Bisagni G; Tinari N; Michelotti A; Zampa G; Gori S; Moscetti L; De Tursi M; Panebianco M; Mauri M; Ferrarini I; Pizzuti L; Ficorella C; Samaritani R; Mentuccia L; Iacobelli S; Gamucci T
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1229-40. PubMed ID: 23604446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.
    Zhang GC; Qian XK; Guo ZB; Ren CY; Yao M; Li XR; Wang K; Zu J; Liao N
    Med Oncol; 2012 Dec; 29(5):3222-31. PubMed ID: 22547076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of HER2 Status by Dual-color in Situ Hybridization Before and After Neoadjuvant Chemotherapy in Breast Cancer.
    Okamura T; Kumaki N; Tsuda B; Niikura N
    Tokai J Exp Clin Med; 2020 Dec; 45(4):176-181. PubMed ID: 33300587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
    Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
    Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.
    Guarneri V; Dieci MV; Barbieri E; Piacentini F; Omarini C; Ficarra G; Bettelli S; Conte PF
    Ann Oncol; 2013 Dec; 24(12):2990-4. PubMed ID: 24013581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
    Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
    Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
    Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
    Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
    Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
    JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.
    Chumsri S; Jeter S; Jacobs LK; Nassar H; Armstrong DK; Emens LA; Fetting JH; Lange JR; Riley C; Tsangaris TN; Wolff AC; Zellars R; Zhang Z; Stearns V
    Clin Breast Cancer; 2010 Feb; 10(1):40-5. PubMed ID: 20133257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
    Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
    Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Hassett MJ; Li H; Burstein HJ; Punglia RS
    Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
    Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
    Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.
    Tanioka M; Sakai K; Sudo T; Sakuma T; Kajimoto K; Hirokaga K; Takao S; Negoro S; Minami H; Nakagawa K; Nishio K
    Breast Cancer Res Treat; 2014 Oct; 147(3):513-25. PubMed ID: 25200445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
    Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
    Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.